Researchers Evaluating Proposed Peritoneal Mesothelioma Staging System
Data gathered by an international group of peritoneal mesothelioma experts is leading to changes in the way patients with this rare asbestos-related disease are diagnosed and treated. The cancer's rarity and resistance to treatment have complicated past efforts to create a formal staging system. Its low incidence also has limited the amount of data necessary to ensure a staging system is useful. Dr. W. Charles Conway, of the Ochsner Cancer Institute in New Orleans, offers insight into a batch of data collected over a 20-year span that is paving the path toward formalizing a staging system for this rare cancer. "The Peri...
Source: Asbestos and Mesothelioma News - September 12, 2014 Category: Environmental Health Authors: Michelle Whitmer Tags: Research & Clinical Trials Source Type: news
Hyperthermic Peritoneal Chemo in Peritoneal Carcinoma...Hyperthermic Peritoneal Chemo in Peritoneal Carcinoma...
Hyperthermic intraperitoneal chemotherapy (HIPEC) can be administered with acceptable morbidity and mortality for selected patients with peritoneal carcinomatosis, according to a new report. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Task Force recommends BRCA mutation screening for high-risk women
According to a new guideline being published in Annals of Internal Medicine, the United States Preventive Services Task Force (USPSTF) recommends that primary care providers screen asymptomatic women with a family history of breast, ovarian, tubal, or peritoneal cancers to determine if that family history may be associated with an increased risk for potentially harmful mutations in breast cancer susceptibility genes BRCA1 or BRCA2. Women who screen positive should have genetic counseling and, if indicated after counseling, BRCA testing. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 23, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
NICE issues ACD on bevacizumab for recurrent advanced platinum sensitive or partially platinum sensitive ovarian, fallopian tube, and primary peritoneal cancer
Source: NICE Area: News The National Institute for Health and Clinical Excellence (NICE) has issued for consultation an Appraisal Consultation Document (ACD) on the use of bevacizumab for treating advanced ovarian cancer that has returned six months or more after initial treatment with platinum-based chemotherapy (platinum-sensitive disease). The following preliminary recommendations have been made: . Bevacizumab in combination with gemcitabine and carboplatin is not recommended for treating the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary ...
Source: NeLM - News - February 1, 2013 Category: Drugs & Pharmacology Source Type: news